Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
palopegteriparatide
- Development stage
- Approved
- Lead developer
- Ascendis Pharma
- Modality
- Peptides, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Palopegteriparatide is a synthetic parathyroid hormone analog used for the treatment of hypoparathyroidism in adults. It is a prodrug consisting of PTH(1-34) conjugated to a methoxy polyethylene glycol (mPEG) carrier via a proprietary TransCon linker, which allows for sustained release and continuous systemic exposure to active PTH. Upon subcutaneous administration, the drug releases active PTH(1-34), mimicking endogenous parathyroid hormone secretion and maintaining stable calcium levels in the body. Palopegteriparatide reduces renal calcium excretion and eliminates the need for supplemental active vitamin D or calcium in many patients. The mechanism of action involves agonism at the parathyroid hormone/parathyroid hormone-related peptide receptor. The drug was first approved by the EMA in November 2023 and by the FDA in August 2024 for use under the brand name Yorvipath. Ascendis Pharma is the developer and manufacturer.
- Brand names
- Yorvipath
- Other names
- TransCon PTHYORVIPATHpalopegteriparatide
02
Targets
PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)
Beyond the preview
Go deeper on palopegteriparatide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on palopegteriparatide.